Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

JAAD Case Reports

Volumn 3, Issue 3, 2017, Pages 208-211

  Birnbaum, Mathew R ^a   Ma, Michelle W ^a   Fleisig, Sarah ^a   Packer, Stuart ^a   Amin, Bijal D ^a   Jacobson, Mark ^a   McLellan, Beth N ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

immune checkpoint inhibitors; immune related adverse events; immunotherapy; nivolumab; programmed cell death 1; sarcoidosis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOCINONIDE; HYDROCORTISONE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; NIVOLUMAB; PACLITAXEL; PREDNISONE;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OINTMENT; PLEURA METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUNCH BIOPSY; SARCOIDOSIS;

EID: 85017534907     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2017.02.015     Document Type: Article

References (10)

1. 1 Opdivo (nivolumab) Prescribing Information, May 2016. Food and Drug Association Website. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf. (Updated May 10, 2016. Accessed September 12, 2016).
2. 2 Danlos, F.X., Pagès, C., Baroudjian, B., et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149:5 (2016), e133–e136.
3. 3 Suozzi, K.C., Stahl, M., Ko, C.J., et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2:3 (2016), 264–268.
4. 4 Montaudié, H., Pradelli, J., Passeron, T., Lacour, J.-P., Leroy, S., Pulmonary sarcoid-like granulomatosis induced by nivolumab [e-pub ahead of print]. Br J Dermatol, 2016, 10.1111/bjd.14808.
5. 5 Keir, M.E., Liang, S.C., Guleria, L., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:4 (2006), 883–895.
6. 6 Francisco, L.M., Salinas, V.H., Brown, K.E., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:13 (2009), 3015–3029.
7. 7 Butte, M.J., Keir, M.E., Phamduy, T.B., Freeman, G.J., Sharpe, A.H., PD-L1 interacts specifically with B7-1 to inhibit T cell proliferation. Immunity 27:1 (2007), 111–122.
8. 8 Celada, L.J., Rotsinger, J.E., Young, A., et al. Programmed death-1 inhibition of PI3K/AKT/mTOR signaling impairs sarcoidosis CD4+ T cell proliferation. Am J Respir Cell Mol Biol 56 (2017), 74–82.
9. 9 Shetty, A., Carter, J.D., Sarcoidosis mimicking lymphoma on FDG-PET imaging. Radiology Case Reports, 6(2), 2011, 409.
10. 10 Amaravadi, R.K., Lippincott-Schwartz, J., Yin, X.-M., et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:4 (2011), 654–666.